{"id":"anxv","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ANXV works by targeting specific proteins in the brain that are involved in the regulation of anxiety. By modulating the activity of these proteins, ANXV aims to reduce anxiety symptoms in patients. Further research is needed to fully understand its mechanism of action.","oneSentence":"ANXV is a small molecule that modulates the activity of certain proteins involved in anxiety disorders.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:11:32.980Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT07259928","phase":"PHASE2","title":"Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion","status":"RECRUITING","sponsor":"Annexin Pharmaceuticals AB","startDate":"2025-11-07","conditions":"Non-Proliferative Diabetic Retinopathy, Retinal Vein Occlusion","enrollment":12},{"nctId":"NCT05532735","phase":"PHASE2","title":"Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Annexin Pharmaceuticals AB","startDate":"2022-08-24","conditions":"Retinal Vein Occlusion","enrollment":16},{"nctId":"NCT04850339","phase":"PHASE1","title":"First in Human Study of ANXV (Recombinant Human Annexin A5) in Healthy Volunteers","status":"COMPLETED","sponsor":"Annexin Pharmaceuticals AB","startDate":"2020-12-21","conditions":"Healthy","enrollment":46}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ANXV","genericName":"ANXV","companyName":"Annexin Pharmaceuticals AB","companyId":"annexin-pharmaceuticals-ab","modality":"Biologic","firstApprovalDate":"","aiSummary":"ANXV is a small molecule that modulates the activity of certain proteins involved in anxiety disorders. Used for Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}